• FDA cleared FoundationOne CDx as a companion diagnostic for Genentech’s Itovebi (inavolisib) regimen in PIK3CA-mutated HR-positive, HER2-negative breast cancer.
• The tissue test expands access beyond FoundationOne Liquid CDx, which received the same companion diagnostic indication in October 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Foundation Medicine Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.